



2017 Cancer Program Annual Report

J. Phillip Citta Regional Cancer Center
Community Medical Center
RWJBarnabas Health

A statistical report of cancer cases seen at RWJBarnabas Health - Community Medical Center (CMC) in 2017. This data is benchmarked against the National Cancer Data Base. Some of the graphical representations include a breakdown of cases by Age, Gender, Race, as well as more site specific data.

Message from the Cancer Committee Chair

The J. Phillip Citta Regional Cancer Center at Community Medical Center, part of the RWJBarnabas System, is proud to produce this report detailing our activities. In it you will find detailed information regarding the type of cancer patients treated at the Cancer Center, with the largest cancer sites including Lung, Breast and Colorectal cancer. You will also find comparisons between our cancer center and national averages as collected by the American College of Surgeons, of which our cancer center is an accredited member. The Cancer Center also is proud to be an Accredited Breast Center of Excellence from the National Accreditation Program of Breast Centers (NAPBC), the only such program in Ocean County.

The J. Phillip Citta Regional Cancer Center offers an array of the latest oncology treatments to meet the challenge of treating cancer in the 21st century. A robust robotic surgery program is supported by 2 Da Vinci surgical robots. The Radiation Oncology department offers treatment on a brand new Varian linear accelerator, along with existing Cyberknife radiosurgery and high dose rate brachytherapy. Medical oncologists treat patients with the latest systemic therapies including immunotherapy based on the latest receptor testing. Multiple support services are offered, including dietary/nutrition counseling, physical therapy/lymphedema therapy, Reiki therapy, and a patient library. The Cancer Center conducts many activities in the community, including Cancer Fairs, free screenings, educational activities, and a well-attended Survivorship Celebration each year.

All of the staff members who work at the Cancer Center are responsible for this wide range of activities, including the caring nurses, therapists, front desk staff, and physicians.

Thank you.

Rajesh Iyer, M.D.
Chairman, Cancer Committee

J. Phillip Citta

Regional Cancer Center

- Designated by the Commission on Cancer (CoC) of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program since 1986.
- Accredited Breast Center of Excellence from the National Accreditation Program of Breast Centers (NAPBC) – first hospital in Ocean and Atlantic Counties
- Gold Award from New Jersey Cancer State Registry (NJCSR) for quality and completeness of 2017 cancer cases.

Cancer Committee Members

- **Rajesh Iyer, MD**, Cancer Committee Chairman, Radiation Oncology
- **Stephen Kupferberg, MD**, Vice Chairperson, Cancer Committee, Cancer Liaison Physician, ENT
- **Chirag Shah, MD**, Medical Oncology/ PI Oncology Research
- **Cynthia Barone, MD**, Radiology
- **Sumy Chang, MD**, Surgery
- **Jane Park, MD**, Surgery
- **Nagy Mikhail, MD**, Pathology /Cancer Conference Coordinator
- **Marianne Holler, DO, F.A.C.O.I.**, Hospice and Palliative Medicine
- **Marley Nicolas, MSN, RN**, Administrative Director Cancer Services
- **Jonathan Gapilango, MSN, RN, OCN, CCRP, NE-BC**, Cancer Program Coordinator/Director Out Patient Cancer Services

Cancer Committee

Members (cont.)

- **Lennette Gonzales, MSHS, RN, OCN, CCRP, Oncology Research Coordinator**
- **Brittany Montalbano, BSN, RN, OCN, QI Coordinator/Survivorship Navigator**
- **Heather Zebrowski, BSN, RN, OCN, 4B-Inpatient Oncology Nursing & Infusion Nursing Service**
- **Kathe Wright, MSN, RN, RN-C, Clinical Breast Navigator**
- **Jane Krong, BSN, RN, OCN, Clinical Lung Navigator**
- **John Lagayada, BSN, RN, OCN, General Navigator**
- **Keri Britske, MBA, BS, Community Outreach Coordinator**
- **Dale Ofei-Ayisi, MA, LCSW, CDP, Psychosocial Services**
- **Veronica Keough, BA, CTR, Cancer Registry Coordinator**
- **Kaitlin Kraft, MS, LGC, Genetic Counselor**
- **Veronica Gajda, RD, CSO, Nutrition Services**
- **Lynne Goldstein, PharmD, RPh, Director, Pharmacy Services**
- **Raymond Howard, PT, DPT, OCS , Director, Rehab Services**
- **Jean Flaherty, Director, Marketing & Communications**
- **Linda Rust, Department Secretary**

Cancer Committee Alternate Members

- **David D'Ambrosio, MD, Radiation Oncology**
- **Bruce Peters, DO, ENT**
- **Gurpreet Lamba, MD, Medical Oncology**
- **Apurv Agrawal, MD, Medical Oncology**
- **Alexander King, MD, Radiology**
- **Malik Deen, MD, Pathology**
- **Tarun Bhandari, MD, Surgery**
- **Tracie B. Mathews, RN, BSN, LCSW, OSW-C, Psychosocial Services**
- **Christina Dambroski, RN, OCN, QI Coordinator**
- **Karen Purcell, BS, Community Outreach Coordinator**
- **Michelle Brunke RN, OCN, 4B-Inpatient Oncology Nursing**
- **Dorothy Moloney, RN, Hospice and Palliative Medicine**
- **Debbie Feeney, BA, CTR, Cancer Registry**

STATISTICAL SUMMARY OF CANCER CASES AT CMC

PATIENT DEMOGRAPHICS

Data from the American Cancer Society's *Facts and Figures for 2017* estimated that there will be over 1,688,780 new cancer cases in 2017, 51,680 will be diagnosed in New Jersey.

In 2017, there were 1461 new cancer cases accessioned at Community Medical Center (CMC).

Of the 1461 cases, the non-analytic cases include 227 that were seen for recurrent or progressive disease (Classes 30-38) and 15 cases that were pathology review cases (Class 43). The following statistical report is based on the remaining 1219 analytic cases, of which, 166 were diagnosed at CMC and went elsewhere for treatment (Class 00), 732 were diagnosed and treated at CMC (Classes 10-14) and 227 were diagnosed at another facility and referred to CMC for treatment (Classes 20-22). **Figure 1** represents a breakdown by class of case.

Medicare was the primary insurance coverage for 67% of patients followed by Managed Care at 17% and 4% Medicaid. Gender distribution revealed 59% females and 41% males. Race distribution included: White: 95%, Black: 2%, and other or unspecified race at 3%. **Figure 2** is a representation by gender and race.

SITE DISTRIBUTION

Figure 3 summarizes the top five analytical primary sites for 2017 which include lung, breast, colorectal, melanoma and prostate.

Class of Case




Figure 1

RACE





Figure 2

TOP 5 SITES



The J. Phillip Citta
Regional Cancer Center
and Infusion Suite



Primary Site	Total (%)	Sex		Class of		Status			Stage Distribution - Analytic Cases Only					
		M	F	Analy	NA	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV	88	Unk
ORAL CAVITY & PHARYNX	36 (2.5%)	27	9	24	12	32	4	0	3	3	4	12	0	2
Lip	3 (0.2%)	2	1	2	1	3	0	0	1	1	0	0	0	0
Tongue	12 (0.8%)	9	3	8	4	10	2	0	2	0	2	3	0	1
Salivary Glands	5 (0.3%)	4	1	4	1	5	0	0	0	2	0	1	0	1
Gum & Other Mouth	4 (0.3%)	2	2	1	3	3	1	0	0	0	1	0	0	0
Tonsil	10 (0.7%)	8	2	7	3	9	1	0	0	0	1	6	0	0
Hypopharynx	2 (0.1%)	2	0	2	0	2	0	0	0	0	0	2	0	0
DIGESTIVE SYSTEM	270 (18.4%)	144	126	224	46	214	56	1	29	45	51	58	11	29
Esophagus	28 (1.9%)	22	6	18	10	18	10	0	0	2	5	7	0	4
Stomach	17 (1.2%)	12	5	15	2	15	2	0	2	2	3	3	0	5
Small Intestine	5 (0.3%)	1	4	4	1	4	1	0	0	1	0	3	0	0
Colon Excluding Rectum	95 (6.5%)	42	53	82	13	77	18	1	13	21	23	17	2	5
Cecum	23	9	14	23	0	21	2	1	4	5	8	2	2	1
Appendix	4	2	2	4	0	4	0	0	0	2	1	1	0	0
Ascending Colon	20	8	12	19	1	14	6	0	2	6	6	4	0	1
Hepatic Flexure	2	1	1	2	0	2	0	0	2	0	0	0	0	0
Transverse Colon	9	3	6	9	0	8	1	0	2	5	2	0	0	0
Descending Colon	4	2	2	2	2	4	0	0	1	1	0	0	0	0
Sigmoid Colon	8	6	2	6	2	5	3	0	1	1	3	1	0	0
Large Intestine, NOS	25	11	14	17	8	19	6	0	1	1	3	9	0	3
Rectum & Rectosigmoid	42 (2.9%)	21	21	38	4	39	3	0	7	9	12	5	0	5
Rectosigmoid Junction	15	5	10	14	1	15	0	0	3	2	7	2	0	0
Rectum	27	16	11	24	3	24	3	0	4	7	5	3	0	5
Anus, Anal Canal & Anorectum	3 (0.2%)	1	2	3	0	3	0	0	0	3	0	0	0	0
Liver & Intrahepatic Bile Duct	25 (1.7%)	17	8	21	4	16	9	0	4	2	1	5	6	3
Liver	23	16	7	20	3	15	8	0	4	2	1	5	5	3
Intrahepatic Bile Duct	2	1	1	1	1	1	1	0	0	0	0	0	1	0
Gallbladder	4 (0.3%)	3	1	4	0	3	1	0	0	1	1	2	0	0
Other Biliary	8 (0.5%)	4	4	6	2	6	2	0	1	0	0	1	1	3
Pancreas	41 (2.8%)	19	22	31	10	31	10	0	2	3	6	15	1	4
Retroperitoneum	1 (0.1%)	1	0	1	0	1	0	0	0	1	0	0	0	0
Other Digestive Organs	1 (0.1%)	1	0	1	0	1	0	0	0	0	0	0	1	0
RESPIRATORY SYSTEM	297 (20.2%)	120	177	266	31	223	74	6	95	26	50	72	4	13
Nose, Nasal Cavity & Middle Larynx	1 (0.1%)	0	1	1	0	1	0	0	0	0	0	1	0	0
Larynx	11 (0.7%)	9	2	9	2	11	0	0	2	4	1	2	0	0
Lung & Bronchus	285 (19.4%)	111	174	256	29	211	74	6	93	22	49	69	4	13
BONES & JOINTS	1 (0.1%)	1	0	0	1	1	0	0	0	0	0	0	0	0
Bones & Joints	1 (0.1%)	1	0	0	1	1	0	0	0	0	0	0	0	0
SOFT TISSUE	11 (0.7%)	8	3	9	2	10	1	0	3	4	2	0	0	0
Soft Tissue (including Heart)	11 (0.7%)	8	3	9	2	10	1	0	3	4	2	0	0	0
SKIN EXCLUDING BASAL & SQUAMOUS CELL CARCINOMA	105 (7.1%)	61	44	85	20	99	6	30	27	12	2	3	0	11
Melanoma -- Skin	101 (6.9%)	59	42	81	20	96	5	30	26	10	2	2	0	11
Other Non-Epithelial Skin	4 (0.3%)	2	2	4	0	3	1	0	1	2	0	1	0	0
BREAST	277 (18.9%)	1	276	239	38	266	11	37	109	53	22	11	0	5
Breast	277 (18.9%)	1	276	239	38	266	11	37	109	53	22	11	0	5
FEMALE GENITAL SYSTEM	91 (6.2%)	0	91	80	11	84	7	1	39	8	12	7	4	9
Cervix Uteri	11 (0.7%)	0	11	10	1	11	0	0	5	0	2	1	1	1
Corpus & Uterus, NOS	56 (3.8%)	0	56	50	6	51	5	0	29	5	5	4	1	6
Corpus Uteri	51	0	51	47	4	47	4	0	28	5	3	4	1	6
Uterus, NOS	5	0	5	3	2	4	1	0	1	0	2	0	0	0
Ovary	15 (1.0%)	0	15	13	2	15	0	0	4	1	5	2	0	1
Vulva	7 (0.5%)	0	7	5	2	7	0	1	1	2	0	0	0	1
Other Female Genital Organs	2 (0.1%)	0	2	2	0	2	0	0	0	0	0	0	2	0
MALE GENITAL SYSTEM	115 (7.8%)	115	0	73	42	104	11	0	23	39	1	9	0	1
Prostate	114 (7.8%)	114	0	72	42	103	11	0	23	39	1	9	0	0
Testis	1 (0.1%)	1	0	1	0	1	0	0	0	0	0	0	0	1
URINARY SYSTEM	76 (5.2%)	48	28	61	15	64	12	26	19	4	1	7	1	3
Urinary Bladder	56 (3.8%)	35	21	48	8	51	5	25	17	4	0	1	1	0
Kidney & Renal Pelvis	19 (1.3%)	12	7	12	7	12	7	0	2	0	1	6	0	3
Ureter	1 (0.1%)	1	0	1	0	1	0	1	0	0	0	0	0	0
BRAIN & OTHER NERVOUS	23 (1.6%)	6	17	16	7	16	7	0	0	0	0	0	16	0
Brain	15 (1.0%)	5	10	11	4	9	6	0	0	0	0	0	11	0
Cranial Nerves Other Nervous	8 (0.5%)	1	7	5	3	7	1	0	0	0	0	0	5	0
ENDOCRINE SYSTEM	48 (3.3%)	8	40	46	2	47	1	0	23	3	9	1	1	9
Thyroid	46 (3.1%)	8	38	44	2	45	1	0	23	3	9	1	0	8
Other Endocrine including Thymus	2 (0.1%)	0	2	2	0	2	0	0	0	0	0	0	1	1
LYMPHOMA	53 (3.6%)	27	26	44	9	44	9	0	23	7	2	10	0	2
Hodgkin Lymphoma	4 (0.3%)	1	3	3	1	4	0	0	2	1	0	0	0	0
Non-Hodgkin Lymphoma	49 (3.3%)	26	23	41	8	40	9	0	21	6	2	10	0	2
NHL - Nodal	30	17	13	26	4	23	7	0	14	3	2	6	0	1
NHL - Extranodal	19	9	10	15	4	17	2	0	7	3	0	4	0	1

Primary Site	Total (%)	Sex		Class of		Status		Stage Distribution - Analytic Cases Only						
		M	F	Analy	NA	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV	88	Unk
MYELOMA	10 (0.7%)	6	4	7	3	8	2	0	0	0	0	0	7	0
Myeloma	10 (0.7%)	6	4	7	3	8	2	0	0	0	0	0	7	0
LEUKEMIA	23 (1.6%)	9	14	16	7	17	6	0	0	0	0	0	16	0
Lymphocytic Leukemia	8 (0.5%)	0	8	5	3	8	0	0	0	0	0	0	5	0
Myeloid & Monocytic Leukemi	12 (0.8%)	7	5	8	4	7	5	0	0	0	0	0	8	0
Acute Myeloid Leukemia	9	4	5	6	3	5	4	0	0	0	0	0	6	0
Chronic Myeloid Leukemia	2	2	0	1	1	1	1	0	0	0	0	0	1	0
Other Myeloid/Monocytic Leu	1	1	0	1	0	1	0	0	0	0	0	0	1	0
Other Leukemia	3 (0.2%)	2	1	3	0	2	1	0	0	0	0	0	3	0
Other Acute Leukemia	2	1	1	2	0	1	1	0	0	0	0	0	2	0
Aleukemic, Subleukemic & 1	1	1	0	1	0	1	0	0	0	0	0	0	1	0
MESOTHELIOMA	3 (0.2%)	3	0	3	0	3	0	0	0	0	1	0	0	2
Mesothelioma	3 (0.2%)	3	0	3	0	3	0	0	0	0	1	0	0	2
MISCELLANEOUS	28 (1.9%)	16	12	24	4	21	7	0	0	0	0	0	24	0
Miscellaneous	28 (1.9%)	16	12	24	4	21	7	0	0	0	0	0	24	0

Table 1 (cont.)

Table 2 & 3 summarize five primary sites for 2017 by gender and compares CMC’s actual cases and the estimated figures form the American Cancer Society (ACS).

MALES		
	CMC	ACS
Prostate	27%	19%
Lung	27%	14%
Colon & Rectum	17%	9%
Bladder	8%	7%
Melanoma	15%	6%

Table 2

FEMALES		
	CMC	ACS
Breast	39%	29%
Lung	25%	14%
Colon & Rectum	11%	9%
Uterus	7%	6%
Thyroid	5%	5%

Table 3

Figure 4 depicts age distribution in comparison with the National Cancer Data Base (NCDB) which is 2015. NCDB data includes cases of all Commission on Cancer Approved Cancer Program hospitals. Thirty percent (30.05%) of patients at CMC were diagnosed between the ages of 70-79 compared to 23.02% at NCDB.

Age at Diagnosis





Figure 4

The American College of Surgeons requires that "unknown" stages should not exceed 10% of the site totals. CMC exceeded requirements for 2017 cases. **Figure 5** is a breakdown of stage for select sites.

Stage at Diagnosis

Percent Unknown



Lung = 5.1%
 Breast = 2.1%
 Prostate = 0%
 Colon = 7.1%
 Bladder = 0%

Figure 5

Figure 6 depicts patient's county at diagnosis. Ninety-nine percent (99%) of CMC new patients in 2017 resided in Ocean County. One percent (1%) resided in other counties/states.

County At Diagnosis




Figure 6



3rd Annual Survivorship Celebration



Community Partners



HEALTHSOUTH.
Rehabilitation Hospital of Toms River
BUILDING A BETTER TOMORROW
[LEARN MORE](#)

